The latest treatments in NASH
Recently, diabetes therapeutics called glitazones (pioglitazone in particular) have been the focus of several studies for NASH treatment and studies show that the use of glitazones can lead to improvements in steatosis, fibrosis and hepatocellular ballooning (damage to liver cells), but at the cost of significant weight gain1.
Current guidelines suggest that pioglitazone can be used for the treatment of steatohepatitis in patients with biopsy-proven NASH2.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Welcome to the Fluid Management Learning Zone. In this Learning Zone we provide an overview of fluid management, including albumin for sepsis and septic shock, guidelines for fluid management in liver cirrhosis and fluid management in cardiac surgery.
Related news and insights
Developed by EPG Health for Medthority in collaboration with Biogen®. This content is intended for healthcare professionals only, and it has been funded and reviewed by Biogen® for scientific accuracy.